NO20050701L - 4-pyrrolidino-fenyl-benzyleter derivater - Google Patents
4-pyrrolidino-fenyl-benzyleter derivaterInfo
- Publication number
- NO20050701L NO20050701L NO20050701A NO20050701A NO20050701L NO 20050701 L NO20050701 L NO 20050701L NO 20050701 A NO20050701 A NO 20050701A NO 20050701 A NO20050701 A NO 20050701A NO 20050701 L NO20050701 L NO 20050701L
- Authority
- NO
- Norway
- Prior art keywords
- pyrrolidino
- phenyl
- benzyl ether
- ether derivatives
- derivatives
- Prior art date
Links
- YOVMEQZKFWKEAI-UHFFFAOYSA-N 1-[4-[phenyl-[phenyl-(4-pyrrolidin-1-ylphenyl)methoxy]methyl]phenyl]pyrrolidine Chemical class C1CCCN1C1=CC=C(C(OC(C=2C=CC=CC=2)C=2C=CC(=CC=2)N2CCCC2)C=2C=CC=CC=2)C=C1 YOVMEQZKFWKEAI-UHFFFAOYSA-N 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 206010039966 Senile dementia Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940052764 dopaminergic anti-parkinson drug mao b inhibitors Drugs 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Racemisk eller enantiomert rene 4-pyrrolidino derivater med formel (I), prosesser for deres fremstilling, farmasytiske preparater omfattende nevnte derivater og anvendelse av disse i forebygging og behandling av sykdom, f.eks. som slike som blir mediert av monoamin oksydase B inhibitorer, spesielt Alzheimers sykdom eller senil demens.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02021319 | 2002-09-20 | ||
| PCT/EP2003/010383 WO2004026826A1 (en) | 2002-09-20 | 2003-09-18 | 4-pyrrolidino-phenyl-benzyl ether derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20050701L true NO20050701L (no) | 2005-03-02 |
Family
ID=32010924
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20050665A NO330012B1 (no) | 2002-09-20 | 2005-02-08 | Pyrrolidonderivater, fremgangsmate for fremstilling av slike, farmasoytisk preparat inneholdende slike, slike forbindelser for behandling av sykdom samt anvendelse av slike for fremstilling av medikament for behandling av sykdom |
| NO20050652A NO329754B1 (no) | 2002-09-20 | 2005-02-08 | Pyrrolidonderivater , farmasoytiske preparater inneholdende slike, slike forbindelserfor behandling av sykdommer samt anvendelse av medikamenter for behandling av skdom |
| NO20050701A NO20050701L (no) | 2002-09-20 | 2005-02-09 | 4-pyrrolidino-fenyl-benzyleter derivater |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20050665A NO330012B1 (no) | 2002-09-20 | 2005-02-08 | Pyrrolidonderivater, fremgangsmate for fremstilling av slike, farmasoytisk preparat inneholdende slike, slike forbindelser for behandling av sykdom samt anvendelse av slike for fremstilling av medikament for behandling av sykdom |
| NO20050652A NO329754B1 (no) | 2002-09-20 | 2005-02-08 | Pyrrolidonderivater , farmasoytiske preparater inneholdende slike, slike forbindelserfor behandling av sykdommer samt anvendelse av medikamenter for behandling av skdom |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US7151111B2 (no) |
| EP (3) | EP1542970B1 (no) |
| JP (3) | JP4335142B2 (no) |
| KR (3) | KR100676014B1 (no) |
| CN (3) | CN100503562C (no) |
| AR (3) | AR041298A1 (no) |
| AT (2) | ATE459601T1 (no) |
| AU (3) | AU2003270213B8 (no) |
| BR (4) | BR0314299A (no) |
| CA (3) | CA2498785C (no) |
| CY (1) | CY1110745T1 (no) |
| DE (2) | DE60331559D1 (no) |
| DK (1) | DK1542970T3 (no) |
| ES (2) | ES2344557T3 (no) |
| GT (3) | GT200300205A (no) |
| HR (3) | HRP20050261A2 (no) |
| JO (2) | JO2604B1 (no) |
| MX (3) | MXPA05002878A (no) |
| MY (3) | MY134480A (no) |
| NO (3) | NO330012B1 (no) |
| NZ (3) | NZ538046A (no) |
| PA (3) | PA8583001A1 (no) |
| PE (3) | PE20050077A1 (no) |
| PL (3) | PL216030B1 (no) |
| PT (1) | PT1542970E (no) |
| RU (3) | RU2323209C2 (no) |
| SI (1) | SI1542970T1 (no) |
| TW (3) | TWI286132B (no) |
| UY (3) | UY27990A1 (no) |
| WO (3) | WO2004026827A1 (no) |
| ZA (3) | ZA200501137B (no) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI286132B (en) * | 2002-09-20 | 2007-09-01 | Hoffmann La Roche | 4-pyrrolidino-phenyl-benzyl ether derivatives |
| GB0314373D0 (en) * | 2003-06-19 | 2003-07-23 | Glaxo Group Ltd | Chemical compounds |
| CN100560566C (zh) * | 2004-08-02 | 2009-11-18 | 弗·哈夫曼-拉罗切有限公司 | 作为maob抑制剂的苄氧基衍生物 |
| KR100845366B1 (ko) * | 2004-08-02 | 2008-07-09 | 에프. 호프만-라 로슈 아게 | 모노아민 산화효소 b 억제제로서 벤질옥시 유도체 |
| UA90708C2 (ru) | 2005-02-25 | 2010-05-25 | Ф. Хоффманн-Ля Рош Аг | Таблетки с улучшенной дисперсностью лекарственного вещества |
| CN101142181B (zh) * | 2005-03-15 | 2011-05-04 | 弗·哈夫曼-拉罗切有限公司 | 对映异构纯的4-吡咯烷子基苯基苄基醚衍生物的制备方法 |
| US7501528B2 (en) * | 2005-03-15 | 2009-03-10 | Hoffmann-La Roche Inc. | Method for preparing enantiomerically pure 4-pyrrolidino phenylbenzyl ether derivatives |
| TW200728258A (en) | 2005-10-10 | 2007-08-01 | Glaxo Group Ltd | Novel compounds |
| TW200730494A (en) | 2005-10-10 | 2007-08-16 | Glaxo Group Ltd | Novel compounds |
| ATE472529T1 (de) * | 2005-10-10 | 2010-07-15 | Glaxo Group Ltd | Prolinamidderivate als natriumkanalmodulatoren |
| WO2008121407A1 (en) * | 2007-03-30 | 2008-10-09 | The Regents Of The University Of California | In vivo imaging of sulfotransferases |
| KR101220182B1 (ko) * | 2009-02-25 | 2013-01-11 | 에스케이바이오팜 주식회사 | 치환된 아졸 유도체 화합물, 이를 포함하는 약제학적 조성물 및 이를 이용한 파킨슨씨 병 치료방법 |
| CZ304053B6 (cs) * | 2011-08-22 | 2013-09-04 | Farmak, A. S. | Zpusob prípravy 2-[4-[(methylamino)karbonyl]-1-H-pyrazol-1-yl]adenosinu monohydrátu |
| KR102018284B1 (ko) * | 2013-02-28 | 2019-09-05 | 삼성디스플레이 주식회사 | 박막 트랜지스터 어레이 기판 및 이를 포함하는 유기 발광 표시 장치 |
| CA2895287A1 (en) | 2013-03-14 | 2014-10-02 | Dart Neuroscience, Llc | Substituted naphthyridine and quinoline compounds as mao inhibitors |
| CZ305213B6 (cs) | 2013-04-29 | 2015-06-10 | Farmak, A. S. | Polymorf E 2-[4-[(methylamino)karbonyl]-1H-pyrazol-1-yl]adenosinu a způsob jeho přípravy |
| EP3063130A1 (en) | 2013-10-29 | 2016-09-07 | F. Hoffmann-La Roche AG | Crystalline forms of a pyrrolidone derivative useful in the treatment of alzheimer's disease and preparation thereof |
| ES2912881T3 (es) | 2014-12-23 | 2022-05-30 | Convergence Pharmaceuticals | Procedimiento para preparar derivados de alfa-carboxamida pirrolidina |
| EP3273946A1 (en) * | 2015-03-27 | 2018-01-31 | F. Hoffmann-La Roche AG | Pharmaceutical formulation comprising sembragiline |
| JP7169592B2 (ja) | 2017-09-27 | 2022-11-11 | 国立大学法人 鹿児島大学 | Pac1受容体拮抗薬を用いた鎮痛薬 |
| EP3691634A4 (en) | 2017-10-05 | 2021-03-31 | Biogen Inc. | PROCESS FOR THE PREPARATION OF PYRROLIDINE ALPHA-CARBOXAMIDE DERIVATIVES |
| CN108299272B (zh) * | 2018-01-31 | 2019-10-18 | 福州大学 | 一种合成1-氯-2,2,2-三氟亚乙基取代咯酮化合物的方法 |
| CA3092747A1 (en) | 2018-03-08 | 2019-09-12 | Sunshine Lake Pharma Co., Ltd. | Pyrrolidineamide derivatives and uses thereof |
| WO2020175134A1 (ja) | 2019-02-27 | 2020-09-03 | 国立大学法人鹿児島大学 | Pac1受容体拮抗薬を用いた鎮痒薬 |
| JP7049637B1 (ja) | 2020-05-08 | 2022-04-07 | 国立大学法人 鹿児島大学 | Pac1受容体拮抗薬を用いた抗うつ・抗不安薬 |
| CN112851561A (zh) * | 2021-01-29 | 2021-05-28 | 南京艾美斐生物医药科技有限公司 | 一种nr6a1蛋白受体抑制剂及其制备和应用 |
| WO2022268520A1 (de) | 2021-06-21 | 2022-12-29 | Bayer Aktiengesellschaft | Verwendung von substituierten pyrrolidinonen oder deren salzen zur steigerung der stresstoleranz in pflanzen. |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4348393A (en) * | 1978-06-09 | 1982-09-07 | Delalande S.A. | N-Aryl oxazolidinones, oxazolidinethiones, pyrrolidinones, pyrrolidines and thiazolidinones |
| FR2500831A1 (fr) * | 1981-02-27 | 1982-09-03 | Delalande Sa | Nouvelles n-aryl-oxazolidinones et -pyrrolidinones |
| JP2657324B2 (ja) | 1989-04-19 | 1997-09-24 | 大塚製薬株式会社 | ヘテロ環を有するフェニルカルボン酸誘導体 |
| CA2198457A1 (en) * | 1994-08-30 | 1996-03-07 | Koichi Kojima | Isoxazole derivatives |
| US5679715A (en) | 1995-06-07 | 1997-10-21 | Harris; Richard Y. | Method for treating multiple sclerosis |
| CA2244253C (en) | 1996-03-15 | 2002-11-12 | Somerset Pharmaceuticals, Inc. | Method for preventing and treating peripheral neuropathy by administering selegiline |
| US5683404A (en) * | 1996-06-05 | 1997-11-04 | Metagen, Llc | Clamp and method for its use |
| DE19841895A1 (de) | 1998-09-11 | 2000-03-23 | Degussa | Neues Verfahren zur Herstellung von 3-Amino-2-oxo-pyrrolidinen, neue Zwischenprodukte und deren Verwendung |
| AU4181000A (en) * | 1999-04-02 | 2000-10-23 | Du Pont Pharmaceuticals Company | Novel lactam inhibitors of matrix metalloproteinases, tnf-alpha, and aggrecanase |
| AU1359801A (en) | 1999-11-05 | 2001-06-06 | Vela Pharmaceuticals Inc. | Methods and compositions for treating reward deficiency syndrome |
| US7621863B2 (en) * | 2000-02-10 | 2009-11-24 | Obtech Medical Ag | Urinary incontinence treatment with wireless energy supply |
| ATE296071T1 (de) * | 2000-02-14 | 2005-06-15 | Potencia Medical Ag | Penisprothese |
| TWI286132B (en) * | 2002-09-20 | 2007-09-01 | Hoffmann La Roche | 4-pyrrolidino-phenyl-benzyl ether derivatives |
| US20040267291A1 (en) * | 2003-06-27 | 2004-12-30 | Byrum Randal T. | Implantable band with non-mechanical attachment mechanism |
| US20040267292A1 (en) * | 2003-06-27 | 2004-12-30 | Byrum Randal T. | Implantable band with transverse attachment mechanism |
-
2003
- 2003-09-17 TW TW092125618A patent/TWI286132B/zh not_active IP Right Cessation
- 2003-09-17 MY MYPI20033545A patent/MY134480A/en unknown
- 2003-09-17 PE PE2003000952A patent/PE20050077A1/es not_active Application Discontinuation
- 2003-09-17 PA PA20038583001A patent/PA8583001A1/es unknown
- 2003-09-18 DE DE60331559T patent/DE60331559D1/de not_active Expired - Lifetime
- 2003-09-18 RU RU2005111969/04A patent/RU2323209C2/ru not_active IP Right Cessation
- 2003-09-18 SI SI200331830T patent/SI1542970T1/sl unknown
- 2003-09-18 ES ES03750564T patent/ES2344557T3/es not_active Expired - Lifetime
- 2003-09-18 HR HR20050261A patent/HRP20050261A2/hr not_active Application Discontinuation
- 2003-09-18 CN CNB038212560A patent/CN100503562C/zh not_active Expired - Fee Related
- 2003-09-18 HR HRP20050263AA patent/HRP20050263B1/hr not_active IP Right Cessation
- 2003-09-18 WO PCT/EP2003/010384 patent/WO2004026827A1/en not_active Ceased
- 2003-09-18 PA PA20038583601A patent/PA8583601A1/es unknown
- 2003-09-18 MY MYPI20033559A patent/MY135696A/en unknown
- 2003-09-18 CN CNB038217678A patent/CN100400509C/zh not_active Expired - Fee Related
- 2003-09-18 PE PE2003000956A patent/PE20050078A1/es not_active Application Discontinuation
- 2003-09-18 KR KR1020057004718A patent/KR100676014B1/ko not_active Expired - Fee Related
- 2003-09-18 AR ARP030103384A patent/AR041298A1/es unknown
- 2003-09-18 NZ NZ538046A patent/NZ538046A/en not_active IP Right Cessation
- 2003-09-18 AU AU2003270213A patent/AU2003270213B8/en not_active Ceased
- 2003-09-18 UY UY27990A patent/UY27990A1/es not_active Application Discontinuation
- 2003-09-18 GT GT200300205A patent/GT200300205A/es unknown
- 2003-09-18 PE PE2003000958A patent/PE20050079A1/es active IP Right Grant
- 2003-09-18 PL PL376021A patent/PL216030B1/pl unknown
- 2003-09-18 AT AT03748052T patent/ATE459601T1/de active
- 2003-09-18 CA CA2498785A patent/CA2498785C/en not_active Expired - Fee Related
- 2003-09-18 JP JP2004537121A patent/JP4335142B2/ja not_active Expired - Fee Related
- 2003-09-18 EP EP03750564A patent/EP1542970B1/en not_active Expired - Lifetime
- 2003-09-18 AT AT03750564T patent/ATE472530T1/de active
- 2003-09-18 US US10/667,087 patent/US7151111B2/en not_active Expired - Lifetime
- 2003-09-18 CA CA2496756A patent/CA2496756C/en not_active Expired - Fee Related
- 2003-09-18 BR BR0314299-0A patent/BR0314299A/pt active Search and Examination
- 2003-09-18 JO JO2003115A patent/JO2604B1/en active
- 2003-09-18 MX MXPA05002878A patent/MXPA05002878A/es active IP Right Grant
- 2003-09-18 BR BR0314631-6A patent/BR0314631A/pt not_active IP Right Cessation
- 2003-09-18 EP EP03757866A patent/EP1542971A1/en not_active Withdrawn
- 2003-09-18 US US10/667,088 patent/US7037935B2/en not_active Expired - Fee Related
- 2003-09-18 MX MXPA05002881A patent/MXPA05002881A/es active IP Right Grant
- 2003-09-18 JO JO2003116A patent/JO2605B1/en active
- 2003-09-18 GT GT200300206A patent/GT200300206A/es unknown
- 2003-09-18 AU AU2003267381A patent/AU2003267381B2/en not_active Ceased
- 2003-09-18 BR BR0314314-7A patent/BR0314314A/pt not_active IP Right Cessation
- 2003-09-18 RU RU2005111974/04A patent/RU2336267C2/ru not_active IP Right Cessation
- 2003-09-18 NZ NZ538049A patent/NZ538049A/en unknown
- 2003-09-18 AR ARP030103385A patent/AR041299A1/es not_active Application Discontinuation
- 2003-09-18 JP JP2004537120A patent/JP4335141B2/ja not_active Expired - Fee Related
- 2003-09-18 CN CNB038219522A patent/CN100383118C/zh not_active Expired - Fee Related
- 2003-09-18 WO PCT/EP2003/010383 patent/WO2004026826A1/en not_active Ceased
- 2003-09-18 ES ES03748052T patent/ES2338646T3/es not_active Expired - Lifetime
- 2003-09-18 PA PA20038583501A patent/PA8583501A1/es unknown
- 2003-09-18 CA CA002498335A patent/CA2498335A1/en not_active Abandoned
- 2003-09-18 KR KR1020057004683A patent/KR100676015B1/ko not_active Expired - Fee Related
- 2003-09-18 UY UY27991A patent/UY27991A1/es not_active Application Discontinuation
- 2003-09-18 DE DE60333202T patent/DE60333202D1/de not_active Expired - Lifetime
- 2003-09-18 MY MYPI20033558A patent/MY133332A/en unknown
- 2003-09-18 GT GT200300204A patent/GT200300204A/es unknown
- 2003-09-18 AU AU2003273901A patent/AU2003273901B2/en not_active Ceased
- 2003-09-18 RU RU2005111968/04A patent/RU2336268C2/ru not_active IP Right Cessation
- 2003-09-18 TW TW092125746A patent/TWI331994B/zh not_active IP Right Cessation
- 2003-09-18 TW TW092125735A patent/TWI337604B/zh not_active IP Right Cessation
- 2003-09-18 BR BRPI0314631-6A patent/BRPI0314631B1/pt unknown
- 2003-09-18 EP EP03748052A patent/EP1542969B1/en not_active Expired - Lifetime
- 2003-09-18 HR HR20050262A patent/HRP20050262A2/xx not_active Application Discontinuation
- 2003-09-18 JP JP2004537119A patent/JP4335140B2/ja not_active Expired - Fee Related
- 2003-09-18 DK DK03750564.1T patent/DK1542970T3/da active
- 2003-09-18 US US10/666,594 patent/US7235581B2/en not_active Expired - Fee Related
- 2003-09-18 KR KR1020057004699A patent/KR100681586B1/ko not_active Expired - Fee Related
- 2003-09-18 AR ARP030103383A patent/AR041297A1/es unknown
- 2003-09-18 MX MXPA05002880A patent/MXPA05002880A/es active IP Right Grant
- 2003-09-18 PL PL03376019A patent/PL376019A1/xx not_active Application Discontinuation
- 2003-09-18 PL PL03376018A patent/PL376018A1/xx not_active Application Discontinuation
- 2003-09-18 PT PT03750564T patent/PT1542970E/pt unknown
- 2003-09-18 WO PCT/EP2003/010356 patent/WO2004026825A1/en not_active Ceased
- 2003-09-18 NZ NZ538048A patent/NZ538048A/en not_active IP Right Cessation
- 2003-09-19 UY UY27993A patent/UY27993A1/es not_active Application Discontinuation
-
2005
- 2005-02-08 NO NO20050665A patent/NO330012B1/no not_active IP Right Cessation
- 2005-02-08 NO NO20050652A patent/NO329754B1/no not_active IP Right Cessation
- 2005-02-08 ZA ZA200501137A patent/ZA200501137B/xx unknown
- 2005-02-09 NO NO20050701A patent/NO20050701L/no not_active Application Discontinuation
- 2005-02-14 ZA ZA200501311A patent/ZA200501311B/en unknown
- 2005-02-22 ZA ZA200501557A patent/ZA200501557B/xx unknown
-
2006
- 2006-01-05 US US11/325,747 patent/US7122562B2/en not_active Expired - Fee Related
-
2010
- 2010-08-20 CY CY20101100770T patent/CY1110745T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20050701L (no) | 4-pyrrolidino-fenyl-benzyleter derivater | |
| NO20082673L (no) | Nye 2-amino-imidazol-4-on forbindelser og deres anvendelse i fremstilling av et medikament som skal brukes til behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerasjon og demens | |
| DK1567488T3 (da) | Hydroxyethylaminderivater til behandling af Alzheimers sygdom | |
| NO20054905L (no) | 2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika | |
| NO20064347L (no) | Substituerte 1,2,3,4-tetrahydroisokinolinderivater | |
| ATE443043T1 (de) | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer | |
| NO20050795L (no) | Forbindelser, blandinger og fremgangsmater for utnyttelse av samme | |
| NO20025601L (no) | Arylmetylaminderivater for anvendelse som tryptaseinhibitorer | |
| NO20081482L (no) | Delta- og epsilon-krystallformer for imatinibmesylat | |
| NO20045677L (no) | Inhibitorer av JAK- og CDK2-proteinkinaser | |
| NO20073628L (no) | Pyridoner som er nyttige som inhibitorer av kinaser | |
| ATE396174T1 (de) | Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten | |
| NO20066055L (no) | Pyridinderivater | |
| NO20064584L (no) | Tetrahydropyridoindolderivater | |
| NO20050290L (no) | Nye tetrahydropyridin-derivater som renin-inhibitorer | |
| NO20050514L (no) | Sammensetning og antiviral aktivitet til substituerte azaindoloksoeddikpiperazinderivater | |
| DE60323765D1 (de) | Inhibitoren der 17 beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten | |
| DK1789398T3 (da) | 2-amino-quinazolin derivater anvendelige som inhibitorer af B-sekretase (BACE) | |
| NO20063137L (no) | Tricykliske indolhydroksyetylaminderivater og deres anvendelse i behandlingen av Alzheimers sykdom | |
| NO20070665L (no) | Derivater av 1-fenylalkankarboksylsyrer for behandlingen av neurodegenerative sykdommer | |
| NO20055624L (no) | Tropanderivater og deres anvendelse som Ace-inhibitorer | |
| NO20062824L (no) | 1,3-Difenylprop-2-en-1-on-avledete forbindelser, fremgangsmater for fremstilling derav, samt anvendelse av samme | |
| NO20060718L (no) | Substituerte tiofoner og deres anvendelse | |
| SG146685A1 (en) | Dihydroporphine derivatives, processes for their preparation, and pharmaceutical compositions containing them | |
| NO20062700L (no) | Morfolinderivater som norepinefrin reopptaksinhibitorer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |